Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Veratect was a pioneer in the field of automated biosurveillance, focusing on the early detection of global infectious disease outbreaks and environmental hazards. The company's core technology, the EPIDEM platform, utilized advanced natural language processing to monitor thousands of open-source data feeds from around the world in real-time. Veratect gained international prominence in 2009 for providing the first alerts regarding the H1N1 swine flu outbreak in Veracruz, Mexico, significantly ahead of official reports from international health organizations. While the company served a diverse client base including government agencies and multinational corporations, it struggled to maintain a sustainable business model in a market with emerging free alternatives. Veratect ceased operations in late 2010, but its legacy remains a significant case study in the evolution of digital epidemiology and pandemic preparedness.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Veratect.